Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)

Completed · Has a placebo group

Conditions studied: Depression

In brief

The purpose of this study is: * To evaluate liothyronine (Cytomel) as an accelerating agent (i.e. faster rate to clinical remission) to electroconvulsive therapy. * To evaluate whether thyroid supplement acceleration can reduce the neurocognitive side effect of ECT treatment. * To evaluate whether thyroid status at the time of remission is associated with subsequent relapse rate. * To evaluate genetic polymorphisms in enzymes responsible for thyroid metabolism and the serotonin transporter promoter gene in depression (5-HTTLRP).

Key facts

Study ID
NCT01299337
Run by
Mayo Clinic
People needed
29
Starts
2008-06-01
Expected to finish
2012-04-01
Last updated by the study team
2012-05-11

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.